Background: Targets for right-sided conduction system pacing (CSP) include His bundle and right bundle branch. ECG patterns, diagnostic criteria and outcomes of right bundle branch pacing (RBBP) are not known. Objective: Our aims were to delineate electrocardiographic and electrophysiological characteristics of RBBP and to compare outcomes between RBBP and His bundle pacing (HBP). Methods: Patients with confirmed right CSP were divided according to the conduction system potential to QRS interval at the pacing lead implantation site. Six hypothesized RBBP criteria as well as pacing parameters, echocardiographic outcomes and all-cause mortality were analyzed. Results: All analyzed criteria discriminated between HBP and LBBP: double QRS transition during threshold test, selective paced QRS different from conducted QRS, stimulus to selective QRS > potential-QRS, small increase in V6RWPT during QRS transition, equal capture thresholds of CSP and myocardium, and stimulus-V6 R-wave peak time (V6RWPT) > potential-V6RWPT (adopted as diagnostic standard). Per this last criterion, RBBP was observed in 19.2% (64/326) patients who had been targeted for HBP, present mainly among patients with potential to QRS < 35 ms (90.6%, 48/53) and occasionally in the remaining patients (5.6%, 16/273). RBBP was characterized by longer QRS (by 10.5 ms), longer V6RWPT (by 11.6 ms) and better sensing (by 2.6 mV) compared to HBP. During median follow-up of 29 months, no differences in capture threshold, echocardiographic outcomes or mortality were found. Conclusions: RBBP is a distinct CSP modality that is frequently observed when the pacing lead is positioned more distally along the right conduction system.

HB: Speaker honoraria, consulting fees or institutional fellowship/research support from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. PV: honoraria, consultant, research, fellowship support: Medtronic, Abbott, Biotronik, Boston Scientific, and Eaglepoint LLC; patent for His delivery tool. MJ: consultant and lecture fees from Medtronic and Abbott.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Jagiellonian University Bioethical Committe

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors